ClinicalTrials.gg
CompletedNCT04305054Updated May 28, 2026

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

A Phase 1/2 interventional study of Pembrolizumab and Vibostolimab in Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed at 60 sites in 14 countries. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
335
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Melanoma by Merck & Co., Inc — 1 open to participants now, 6 under way, 3 of them phase 3. Melanoma · Merck & Co., Inc.

Enrollment
11th of 39
335 · median 131
Started
2020
with 4 others
Phase 1/2
9 of 42
1 open now
Registered
33rd of 42
by date

Among the 42 studies in Melanoma by Merck & Co., Inc, this one is the 11th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2020, is one of 9 in phase 1/2, and was the 33rd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

1 of the 42 studies in Melanoma by Merck & Co., Inc is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Melanoma by Merck & Co., Inc, or all of them as a file.
02

Study summary

Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated before. The larger study is the umbrella study. Researchers want to know if adding other treatments to pembrolizumab can treat advanced melanoma. The goals of this study are to learn:

  • About the safety and how well people tolerate pembrolizumab given with other treatments
  • How many people have melanoma that responds (gets smaller or goes away) to treatment
Read the detailed description

With Amendment 6, all arms are closed to enrollment. Participants in arms 2 (pembrolizumab), 3 (coformulation pembrolizumab/quavonlimab), and 4 (coformulation pembrolizumab/quavonlimab + lenvatinib) who complete study treatment or otherwise meet end of treatment (EOT) criteria will be discontinued from the study after completing the EOT visit and any required safety follow-up visits. Participants in arm 6 (coformulation favezelimab/pembrolizumab + All-trans Retinoic Acid [ATRA]) will discontinue ATRA and participants in arms 5 and 6 can continue on coformulation favezelimab/pembrolizumab or pembrolizumab.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death ligand 1 (PD-L1, PDL1)
  • T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine receptor motif domains (TIGIT)
  • Cytotoxic T lymphocyte associated protein 4 (CTLA4)
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically confirmed melanoma
  • Has unresectable Stage III or Stage IV melanoma, not amenable to local therapy
  • Has been untreated for advanced disease.
  • Has provided a tumor
  • If capable of producing sperm, male participants agree to the following during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention (7 days):

    • Abstains from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agrees to remain abstinent OR
    • Uses unless confirmed to be azoospermic
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

    • Is not a OR
    • Is a WOCBP and Uses a contraceptive method that is highly effective, with low user dependency, or be abstinent from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention. The length of time required to continue contraception for each study intervention is:
    • MK-4280A: 120 days
    • MK-1308A: 120 days
    • MK-7684: 50 days
    • MK-3475: 120 days
    • Lenvatinib: 30 days
    • ATRA: 30 days
  • Has adequate organ function
  • Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia and Grade 2 neuropathy)

Exclusion criteria

Exclusion Criteria:

  • Has a diagnosis of immunodeficiency or is receiving therapy within 7 days before the first dose of study intervention
  • Has a known additional that is progressing or requires active treatment within the past 2 years
  • Has known central nervous system (CNS) and/or carcinomatous meningitis
  • Has ocular or mucosal melanoma
  • Has an active disease that has required systemic treatment in the past 2 years
  • Has an active infection requiring systemic therapy
  • Has known history of (HIV)
  • Has history of or known virus infection
  • Has a history of (noninfectious) pneumonitis
  • Has a history of active tuberculosis (TB)
  • Has received prior systemic anticancer therapy within 4 weeks prior to randomization
  • Has received prior radiotherapy within 2 weeks of first dose of study intervention
  • Has had major surgery \<3 weeks prior to first dose of study intervention
  • Has received a within 30 days before the first dose of study intervention
  • Has participated in a study of an agent within 4 weeks prior to the first dose of study intervention
  • Has had an allogeneic tissue/solid organ transplant
  • Has a known psychiatric or substance abuse disorder that would interfere with requirements of the study
  • Participants who receive lenvatinib have the following additional exclusion criteria:

    • Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula
    • Has radiographic evidence of encasement of invasion of a major blood vessel, or of intratumoral cavitation
    • Has hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study intervention
    • Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
    • Has urine protein ≥1 g/24-hour.
    • Has presence of gastrointestinal condition including malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
335 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Vibostolimab

    Participants will receive pembrolizumab intravenously (IV) plus vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.

    Biological: Pembrolizumab · Biological: Vibostolimab

  • Active comparator
    Pembrolizumab

    Participants will receive pembrolizumab IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.

    Biological: Pembrolizumab

  • Experimental
    Coformulation Pembrolizumab/Quavonlimab

    Participants will receive coformulation of pembrolizumab and quavonlimab (MK-1308A) IV at a specified dose on specified days for a total treatment duration of up to approximately 2 years.

    Biological: Pembrolizumab · Biological: Pembrolizumab/Quavonlimab

  • Experimental
    Coformulation Pembrolizumab/Quavonlimab + Lenvatinib

    Participants will receive coformulation of pembrolizumab and quavonlimab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.

    Biological: Pembrolizumab · Biological: Pembrolizumab/Quavonlimab · Drug: Lenvatinib

  • Experimental
    Coformulation Favezelimab/Pembrolizumab

    Participants will receive cofomulation of favezelimab + pembrolizumab (MK-4280A) IV at specified dose on specified days every 3 weeks (Q3W) for up to approximately 2 years

    Biological: Favezelimab/Pembrolizumab

  • Experimental
    Coformulation Favezelimab/Pembrolizumab + All-trans Retinoic Acid (ATRA)

    Participants will receive coformulation of favezelimab and pembrolizumab IV Q3W for up to 35 cycles, plus ATRA orally (for 3 days surrounding each infusion of MK-4280A, including Days 1, 2, and 3 of Cycle 1 and on Days -1, 1, and 2 of all subsequent cycles).

    Drug: ATRA

  • Experimental
    Coformulation Favezelimab/Pembrolizumab + Vibostolimab

    Participants will receive coformulation of favezelimab and pembrolizumab (MK-4280A) IV and vibostolimab IV at specified doses on specified days for a total treatment duration of up to approximately 2 years.

    Biological: Vibostolimab · Biological: Favezelimab/Pembrolizumab

Interventions

  • BiologicalPembrolizumab

    Administered via IV infusion at a specified dose on specified days

    Also known as: MK-3475, KEYTRUDA®

  • BiologicalVibostolimab

    Administered via IV infusion at a specified dose on specified days

    Also known as: MK-7684

  • BiologicalPembrolizumab/Quavonlimab

    Drug page: Pembrolizumab/Quavonlimab MK-1308A

    Administered via IV infusion at a specified dose on specified days

    Also known as: MK-1308A

  • Administered via oral capsule at a specified dose on specified days

    Also known as: MK-7902, E7080, LENVIMA®

  • BiologicalFavezelimab/Pembrolizumab

    Drug pages: Favezelimab · Pembrolizumab

    Administered via IV infusion at a specified dose on specified days

    Also known as: MK-4280A

  • DrugATRA

    Administered via oral capsule at a specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Percentage of participants who experience a dose-limiting toxicity (DLT): Safety lead-in phase

    The percentage of participants who experience 1 or more protocol-defined DLTs during the safety lead-in period will be reported.

    Time frame: Up to ~3 weeks

  2. Percentage of participants who experience an adverse event (AE): Safety lead-in

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experience an AE during the safety lead-in period will be reported.

    Time frame: Up to ~3 weeks

  3. Percentage of participants who discontinue study treatment due to an AE: Safety lead-in

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study treatment due to an AE during the safety lead-in will be reported.

    Time frame: Up to ~3 weeks

  4. Percentage of participants who experience an adverse event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experience an AE will be reported.

    Time frame: Up to ~28 months

  5. Percentage of participants who discontinue study treatment due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to ~24 months

  6. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)

    ORR is defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 has been modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to ~30 months

Secondary outcomes

  1. Duration of Response (DOR) per RECIST 1.1

    For participants in the analysis population who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 as assessed by BICR. RECIST 1.1 has been modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to ~30 months

07

Study locations

60 sites
  • The Angeles Clinic and Research Institute ( Site 2009)
    Los Angeles, California 90025, United States
  • UCLA Hematology & Oncology ( Site 2004)
    Los Angeles, California 90095, United States
  • Providence Saint John's Health Center ( Site 2010)
    Santa Monica, California 90404, United States
  • University of Colorado, Anschutz Cancer Pavilion ( Site 2012)
    Aurora, Colorado 80045, United States
  • University of Florida College of Medicine-UF Health Cancer Center/Clinical Trials Office ( Site 2026)
    Gainesville, Florida 32608, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 2022)
    Baltimore, Maryland 21287, United States
  • R.J. Zuckerberg Cancer Center ( Site 2032)
    Lake Success, New York 11042, United States
  • NYU Clinical Cancer Center ( Site 2002)
    New York, New York 10016, United States
  • Duke Cancer Institute ( Site 2005)
    Durham, North Carolina 27710, United States
  • Martha Morehouse Tower ( Site 2020)
    Columbus, Ohio 43221, United States
  • Oregon Health & Science University ( Site 2013)
    Portland, Oregon 97239, United States
  • University of Pennsylvania Abramson Cancer Center ( Site 2008)
    Philadelphia, Pennsylvania 19104, United States
  • West Cancer Center - East Campus ( Site 2014)
    Germantown, Tennessee 38138, United States
  • Mays Cancer Center ( Site 2025)
    San Antonio, Texas 78229, United States
  • Inova Schar Cancer Institute ( Site 2011)
    Fairfax, Virginia 22031, United States
  • Clinica Adventista Belgrano-Oncology ( Site 2242)
    Caba., Buenos Aires C1430EGF, Argentina
  • Instituto Alexander Fleming-Alexander Fleming ( Site 2243)
    Buenos Aires, Buenos Aires F.D. 1426ANZ, Argentina
  • Sanatorio Finochietto ( Site 2245)
    Buenos Aires, C1187AAN, Argentina
  • Calvary Mater Newcastle-Medical Oncology ( Site 2404)
    Waratah, New South Wales 2298, Australia
  • Melanoma Institute Australia ( Site 2402)
    Wollstonecraft, New South Wales 2065, Australia
  • Tasman Oncology Research Pty Ltd ( Site 2403)
    Southport, Queensland 4120, Australia
  • Fiona Stanley Hospital ( Site 2401)
    Murdoch, Western Australia 6150, Australia
  • CIDO SpA-Oncology ( Site 2256)
    Temuco, Araucania 4810218, Chile
  • IC La Serena Research ( Site 2254)
    La Serena, Coquimbo Region 1720430, Chile
  • FALP-UIDO ( Site 2251)
    Santiago, Region M. de Santiago 7500921, Chile
  • Oncovida ( Site 2257)
    Santiago, Region M. de Santiago 7500994, Chile
  • Bradfordhill ( Site 2252)
    Santiago, Region M. de Santiago 8420383, Chile
  • Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 2261)
    Bogotá, Bogota D.C. 111321, Colombia
  • Fundación Valle del Lili ( Site 2265)
    Cali, Valle del Cauca Department 760032, Colombia
  • Hopital La Timone ( Site 2103)
    Marseille, Bouches-du-Rhone 13005, France
  • CHU de Bordeaux- Hopital Saint Andre ( Site 2108)
    Bordeaux, Gironde 33075, France
  • Institut Claudius Regaud ( Site 2105)
    Toulouse, Haute-Garonne 31059, France
  • C.H. Lyon Sud ( Site 2102)
    Pierre-Bénite, Rhone 69495, France
  • A.P.H. Paris, Hopital Saint Louis ( Site 2107)
    Paris, 75010, France
  • Gustave Roussy ( Site 2101)
    Villejuif, Île-de-France Region 94805, France
  • General Hospital of Athens "Laiko"-First Department of Internal Medicine ( Site 2212)
    Athens, Attica 115 26, Greece
  • European Interbalkan Medical Center-Oncology Department ( Site 2211)
    Thessaloniki, 570 01, Greece
  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ ( Site 2221)
    Szeged, Csongrád megye 6720, Hungary
  • HaEmek Medical Center ( Site 2703)
    Afula, 1834111, Israel
  • Rambam Health Care Campus-Oncology ( Site 2704)
    Haifa, 3109601, Israel
  • Hadassah Ein Karem Jerusalem ( Site 2702)
    Jerusalem, 9112001, Israel
  • Rabin Medical Center-Oncology ( Site 2705)
    Petah Tikva, 4941492, Israel
  • Chaim Sheba Medical Center ( Site 2701)
    Ramat Gan, 5265601, Israel
  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 2399)
    Milan, 20133, Italy
  • Istituto Europeo di Oncologia ( Site 2301)
    Milan, 20141, Italy
  • Istituto Nazionale Tumori Fondazione Pascale ( Site 2302)
    Naples, 80131, Italy
  • Istituto Oncologico Veneto IRCCS ( Site 2355)
    Padova, 35128, Italy
  • Policlinico Le Scotte - A.O. Senese ( Site 2377)
    Siena, 53100, Italy
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 2233)
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 2231)
    Gdansk, Pomeranian Voivodeship 80-952, Poland
  • CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 2865)
    Port Elizabeth, Eastern Cape 6055, South Africa
  • Steve Biko Academic Hospital-Medical Oncology ( Site 2862)
    Pretoria, Gauteng 0002, South Africa
  • LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 2861)
    Pretoria, Gauteng 0181, South Africa
  • Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 2863)
    Sandton, Gauteng 2196, South Africa
  • Cape Town Oncology Trials ( Site 2864)
    Cape Town, Western Cape 7570, South Africa
  • HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Site 2801)
    Barcelona, Catalonia 08036, Spain
  • Hospital Universitario Ramón y Cajal ( Site 2802)
    Madrid, Madrid, Comunidad de 28034, Spain
  • Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 2603)
    Geneva, Canton of Geneva 1211, Switzerland
  • CHUV Centre Hospitalier Universitaire Vaudois ( Site 2602)
    Lausanne, Canton of Vaud 1011, Switzerland
  • Universitaetsspital Zuerich ( Site 2601)
    Zuerich Flughafen, Canton of Zurich 8058, Switzerland
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in May 2026, 70 months.

Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's 70 months is above that.

Counting every sponsor, half of 220 studies reached it within 61 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2020
First posted
Mar 12, 2020
StartActual
Jul 1, 2020
Primary completionActual
May 18, 2026
CompletionActual
May 18, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04305054
Responsible party
Sponsor
First posted
Mar 12, 2020
Start date
Jul 1, 2020
Primary completion
May 18, 2026
Completion
May 18, 2026
Last update
May 28, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vibostolimab · Pembrolizumab/Quavonlimab MK-1308A · Lenvatinib · Favezelimab · Pembrolizumab · Tretinoin

Start the discussion